Parkinson's Research Understanding Stem Cell Therapy in Parkinsons Disease Treatment
On April 29, 2018, the Washington Post published an article examining commercial stem cell clinics in the United States that market non-FDA approved treatments directly to the public for a variety of health issues, including arthritis, macular degeneration and of particular note to us, Parkinsons disease (PD).
A typical treatment at one of these clinics involves removing fat cells from the abdomen (some clinics remove bone marrow or blood for this procedure), treating the cells in various ways in order to isolate mesenchymal stem cells or stromal cells from the removed tissue, and finally injecting these cells back into the body. The cells are re-introduced into the body in different locations (into the bloodstream, cerebral spinal fluid, nose, eye, etc.) depending on which disease is being targeted. Such treatments are performed for a fee, sometimes a large one, and are not covered by insurance.
Commercial clinics do not as a rule publish their results in peer-reviewed journals to demonstrate to the scientific community that the treatments work. Rather, they usually rely on anecdotes from patients as proof of efficacy. Some clinics are tracking their results by measuring variables such as quality of life before or after the procedure. However, without comparing the patients to a similar group who does not receive the treatment, it is hard to know whether any improvement is due to placebo effect or to the treatment itself.
Safety data is also limited, although there have been some publicized lawsuits claiming that these treatments resulted in harm. Stem cell researchers in general question whether cells harvested in such a way contain sufficient amounts of adult-derived stem cells to be meaningful. It is also unclear how this type of procedure would target the stem cells to the correct location. If stem cells are introduced in the nose for example, it is unclear how they would find their way to the basal ganglia and make the correct connection in order to help a person with Parkinsons disease.
In order for the medical community to accept this type of treatment as safe and beneficial, it would need to be shown to work in a placebo-controlled clinical trial for which participants do not pay, are aware of the known risks and benefits, and are carefully monitored throughout the trial. In addition, the trial would need to track adverse events, as well as record and share the outcomes of trial participants as they compare to the group of patients receiving a placebo treatment. So far this has not happened. The FDA is in fact studying mesenchymal stem cells in the laboratory in order to determine the best way to use them to help people, but these studies have not yet led to approved treatments. Most recently, the FDA filed federal complaints against two clinics that are marketing stem cell products without regulatory approval.
Researchers are working on it. Stem cells, often derived from a patient with Parkinsons disease, are currently being studied extensively in the laboratory, both to further our understanding of the molecular mechanisms that cause cell death in PD, and also as a test environment for new medications. However, there are currently no stem cell treatments for Parkinsons disease that have been developed and tested to the point that we are sure that they help and do not cause harm. Researchers however, are furiously underway to develop such a treatment. The research is focused on deciphering the best source of stem cells to use, the best ways to turn the stem cells into dopaminergic neurons (the type of neurons that are depleted in Parkinsons disease) and the best ways to introduce the cells into the brain for maximal effect and minimal harm.
1. Embryonic stem cells (ESCs) Stem cells derived from a human embryo, typically at a very early developmental stage. Early embryos created by in vitro fertilization (IVF) and are not going to be used, are typically the source of these cells. (This is as opposed to fetal stem cells which are typically derived from an older embryo.) 2. Adult derived stem cells (also called tissue-specific stem cells) Stem cells found among, and then isolated from, differentiated cells in an adult. The most well understood of these are hematopoietic stem cells found in adult blood and bone marrow, which have been used clinically for decades, mostly to treat blood cancers and other disorders of the blood and immune systems. 3. Umbilical cord stem cells Hematopoietic stem cells are also found in umbilical cord blood retrieved after delivery. These too are used clinically to treat blood cancers and some rare genetic disorders 4. Mesenchymal stem cells also known as stromal cells are present in many tissues such as bone, cartilage and fat. They remain poorly understood, but likely have regenerative potential. These are the cells that are harvested at the commercial stem cell clinics described above. 5. Induced pluripotent stem cells (iPSCs) Stem cells created from adult skin or blood cells that have been reprogrammed to revert to an embryonic state. 6. Human parthenogenetic stem cells Stem cells created from an unfertilized human ovum.
Four groups dedicated to using stem cell therapies to treat Parkinsons disease have formed an international consortium known as G Force PD. Each of the four centers is planning a clinical trial to start in the next 1-4 years. They differ on the source of stem cells that they will be using (ESCs vs iPSCs). All will be injecting the cells directly into the basal ganglia part of the brain where the ends of the dopamine producing neurons live. The Parkinsons community eagerly awaits the implementation of these trials.
When open for enrollment, should I consider participating in a stem cell trial? When faced with an illness like PD, you can at times feel that it is worthwhile to try anything that may lead to a cure. Its important to always make sure however, that youre dealing with trusted information, proven therapies, and clinical trials that have been properly vetted by the medical community.
What if you want to get involved? Participation in a clinical trial that is investigating the use of stem cell treatments for Parkinsons disease will allow you to be involved in bringing such treatments to fruition. It is incredibly important to note however, that clinical trials that are entered on clinicaltrials.gov, the NIH-managed directory of all clinical trials, are not vetted by the NIH, and commercial stem cell clinics we mentioned earlier can put their treatments on this site to recruit patients. Most people dont realize this, which led clinicaltrials.gov to put a new disclaimer on their site stating: The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
Therefore, in order to use clinicaltrials.gov safely, focus on the trials conducted at academic medical centers in the United States. Once you have identified a trial that you might be interested in, talk it over with your doctor before committing to anything.
Be aware that a clinical trial utilizing stem cells will likely require the cells to be injected directly into the brain, which will inevitably be associated with a certain amount of risk. You will need to discuss details of this risk with your doctor and the trial organizers.
Does APDA fund any stem cell research? APDA is committed to funding research to further our understanding of PD and to bring new treatments to patients as quickly as possible. Recent funding of Dr. Xiabo Mao, at Johns Hopkins University School of Medicine in Baltimore, MD, allowed him to use iPSCs to model PD and test a potential new avenue of treatment.
Be cautious of any clinic promoting a treatment that has not been proven by the FDA to be safe and effective. There is some promise in the area of using stem cells as a possible treatment for PD, but much more research needs to be done before such a therapy will be approved for clinical use.
Do you have a question or issue that you would like Dr. Gilbert to explore? Suggest a Topic
DISCLAIMER: Any medical information disseminated via this blog is solely for the purpose of providing information to the audience, and is not intended as medical advice. Our healthcare professionals cannot recommend treatment or make diagnoses, but can respond to general questions. We encourage you to direct any specific questions to your personal healthcare providers.
- Aspen Neuroscience gets funding to pursue personalized cell therapy for Parkinsons disease - The San Diego Union-Tribune - December 14th, 2019
- Acute Leukemia: 5 Things to Know - Medscape - December 14th, 2019
- Global T-Cell Therapy (CAR T-Cell, Tumor Infiltrating Lymphocytes) Market Size, Share & Trends Analysis Report 2019-2026 - ResearchAndMarkets.com... - December 14th, 2019
- CAMPUS: EGG DONATION - Artificial sperm cells to remove the genetic worries of sperm donation - ESHRE - December 14th, 2019
- Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2045 2017 - 2025 - Markets Gazette 24 - December 14th, 2019
- Aspen Neuro Bags $6.5M to Test Parkinson's Disease Stem Cell Therapy - Xconomy - December 13th, 2019
- LentiGlobin Gene Therapy Continues to Show Promising Results in SCD, Updated Trial Data Shows - Sickle Cell Anemia News - December 13th, 2019
- CHMP Issues Positive Opinion Recommending DARZALEX (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple... - December 13th, 2019
- Treatment Characteristics and Outcomes for Patients With Rare Forms of T-Cell Lymphoma - Hematology Advisor - December 13th, 2019
- Researchers ID Molecule that Appears to Halt and Reverse Scarring in Fibrotic Diseases - BioSpace - December 13th, 2019
- Canine Stem Cell Therapy Market with Future Prospects, Key Player SWOT Analysis and Forecast To 2024 - Tech Estate Today - December 13th, 2019
- StemGenex - Stem Cell Therapy, Stem Cell Treatments, Stem ... - December 11th, 2019
- Cutting Edge Exosome Regenerative Therapy Comes to Yelm's AM Medical - ThurstonTalk - December 11th, 2019
- Sickle Cell Disease: Ex Vivo Cell Therapy Shines in Early Study - MedPage Today - December 11th, 2019
- Five recent drug target discoveries for pancreatic cancer - Drug Target Review - December 11th, 2019
- Immunotherapy drug improves outcomes for some children with relapsed leukemia - National Institutes of Health - December 11th, 2019
- 20(R)-Ginsenoside Rg3 Influences Cancer Stem Cell Properties and the E | OTT - Dove Medical Press - December 11th, 2019
- Patients closer to receiving regenerated tissue, scientists say - The Irish News - December 11th, 2019
- The Knesset dissolves and the public suffers - Ynetnews - December 11th, 2019
- Global T-Cell Therapy Market: Trends, Opportunities and Forecasts (2019-2026) - Therapy for Solid Tumors Expected to Emerge as a Lucrative Source of... - December 11th, 2019
- Layoffs at Fla.-based stem cell clinic accused of aggressively marketing patients - ABC Action News - December 11th, 2019
- Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of US Patent for Method of Generating Induced Pluripotent Stem Cells - BioSpace - December 11th, 2019
- New Mechanism of Bone Maintenance and Repair Discovered - Technology Networks - December 11th, 2019
- BMS' oral maintenance therapy boosts survival in AML patients - PMLiVE - December 11th, 2019
- Autoimmune Technologies Announces New Subsidiary to Develop Novel Antibody and Allogeneic Somatic Stem Cell Therapeutics For the Treatment of Invasive... - December 10th, 2019
- Microbial Dynamics in Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation - Oncology Nurse Advisor - December 10th, 2019
- CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients... - December 10th, 2019
- Celularity Presents Pre-Clinical and Clinical Data from its Allogeneic, Placental-Derived, Off-the-Shelf Cell Therapy Platform at the 2019 ASH Annual... - December 10th, 2019
- Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug... - December 10th, 2019
- Novartis sets 2020 target for commercial readiness of cell therapy CMO - BioPharma-Reporter.com - December 10th, 2019
- Stadius Biopharma to Present Data on Fully Human Antibodies for the Treatment of Candida Infections - P&T Community - December 10th, 2019
- Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019... - December 10th, 2019
- ASH 2019: Second-gen CAR T-Cell Therapy Overcome Resistance, Reduce Toxicity and Simplify Treatment - OncoZine - December 10th, 2019
- IFN-: The T cell's license to kill stem cells in the inflamed intestine - Science - December 8th, 2019
- Movies opening in L.A. this week: 'Bombshell,' 'Jumanji: The Next Level' and more - Los Angeles Times - December 8th, 2019
- Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of... - December 8th, 2019
- Stem Cell Alopecia Treatment Market 2019 Business Growth, Size and Comprehensive Research Study Forecast to 2026 - Montana Ledger - December 8th, 2019
- Jasper Therapeutics launches out of Stanford with new approach to stem cell treatment - Endpoints News - December 7th, 2019
- MaaT Pharma Announces the Presentation of Positive Data with Its Lead Microbiome Biotherapeutic in Intestinal-Predominant Acute... - December 7th, 2019
- Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers - GlobeNewswire - December 7th, 2019
- Sickle Cell Anemia Patient Becomes First Person in the US to Have Her Genes Edited With CRISPR - Interesting Engineering - December 7th, 2019
- Teen diagnosed with cancer again just months after being told he beat disease - Mirror Online - December 7th, 2019
- Living with cancer: 'Exercising during my chemotherapy treatment worked wonders' - inews - December 7th, 2019
- Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis - Business Wire - December 7th, 2019
- Stem cells may trigger immune repair to mend hearts - BioNews - December 5th, 2019
- Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic... - December 5th, 2019
- Hunter Syndrome Treatment Market Size, Share & Trend Analysis By Treatment, By Region And Segment Forecasts, 2019 - 2026 - P&T Community - December 5th, 2019
- Platelet Rich Plasma and Stem Cell Alopecia Treatment Market is on Course to Expand at a CAGR of XX% Over the Forecast Period 2018 - 2026 - Weekly Spy - December 5th, 2019
- miR-194 Inhibits the Proliferation of SW620 Colon Cancer Stem Cells Th | CMAR - Dove Medical Press - December 5th, 2019
- Stem Cell Therapy Market Growth opportunities, Trends, Industry Analysis, and Forecast to 2020 - Kentucky Reports - December 5th, 2019
- As per new Study on Stem Cell Therapy Market 2019 Future Strategy, Analysis and Prediction by Leading Manufacturers, its Application and Types... - December 5th, 2019
- Stem Cell Therapy Market Size, Share, Trends, and Opportunity Analysis by 2017 - 2025 - The Market Expedition - December 5th, 2019
- Newly approved sickle cell drug ushers in an era of therapeutic breakthroughs - Worcester Telegram - December 5th, 2019
- A new stem cell therapy promises to heal injured heart - TheHealthSite - December 5th, 2019
- Harnessing Gamma T Cells To Bring Effective Therapies to Patients - Technology Networks - November 30th, 2019
- Phase 2 Trial Data on ALS NurOwn Therapy, Supporting Safety And Early Efficacy, Published - ALS News Today - November 30th, 2019
- Proof-of-Concept Study of CAR-NK Cell Therapy with Engineered Persistence Shows Potential - Cancer Network - November 29th, 2019
- Mum shares heartbreaking photo of toddler sobbing through gruelling cancer treatment - The Sun - November 29th, 2019
- Mesenchymal Stem Cells Market Key Trends, Key Players, Challenges And Standardization, Analysis Of Key Players, And Forecast To 2026 - WindStreetz - November 29th, 2019
- Bone Therapeutics SA: Information on the total number of voting rights and shares - GlobeNewswire - November 29th, 2019
- Induction Therapy and Hematopoietic Stem Cell Transplantation for Mixed-Phenotype Acute Leukemia - Cancer Therapy Advisor - November 28th, 2019
- Why Stem Cell Therapy Might Be Your Answer To Chronic Pain - Patch.com - November 28th, 2019
- North-east toddler overcomes cancer after pioneering stem cell treatment - Press and Journal - November 28th, 2019
- Revolutionary stem cell banking and therapy from Celltex gives patients hope - KHOU.com - November 28th, 2019
- Kyoto University seeks approval to use stem cells in treatment for damaged knees - The Japan Times - November 28th, 2019
- Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy - Science Advances - November 28th, 2019
- Sickle Cell Disease: Current Treatment and Emerging Therapies - AJMC.com Managed Markets Network - November 28th, 2019
- Vertex plans major Boston expansion to support gene, cell therapy ambitions - FiercePharma - November 28th, 2019
- Discovery of 'Tendon Stem Cells' Could Revolutionize How We Recover From Injuries - Good News Network - November 28th, 2019
- You can take my Dads tweets over my dead body - TechCrunch - November 28th, 2019
- From Tiger Woods to Brooks Koepka, the 9 things we learned this fall on PGA Tour - Golf Channel - November 28th, 2019
- Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Future Growth, Industry Verticals, and Research Forecast upto 2026 - The Denton Chronicle - November 28th, 2019
- Stem Cell Therapy Market Gain Impetus due to the Growing Demand over 2025 - Guru Online News - November 28th, 2019
- Stem Cell Therapy Market Size, by Therapeutic Application (Musculoskeletal Disorders, Wounds and Injuries), by Cell Source (Adipose Tissue-derived... - November 28th, 2019
- Global Musculoskeletal Disorder Stem Cell Therapy Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - Avon Lake Ledger - November 28th, 2019
- Translink in Armagh holding stem cell registration event in memory of Gavin McNaney - Armagh i - November 28th, 2019
- Induction Therapy and Hematopoietic Stem Cell Transplantation for Mixed-Phenotype Acute Leukemia - Hematology Advisor - November 25th, 2019
- Tendon stem cell discovery could lead to improvements in injury recovery - Drug Target Review - November 25th, 2019
- 2 Small-Cap Biotechs That Soared Last Week - Motley Fool - November 25th, 2019
- Cell Culture Market Size to Exceed US $42 Billion by 2026 - Post Register - November 25th, 2019